MX2017003886A - Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales. - Google Patents
Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales.Info
- Publication number
- MX2017003886A MX2017003886A MX2017003886A MX2017003886A MX2017003886A MX 2017003886 A MX2017003886 A MX 2017003886A MX 2017003886 A MX2017003886 A MX 2017003886A MX 2017003886 A MX2017003886 A MX 2017003886A MX 2017003886 A MX2017003886 A MX 2017003886A
- Authority
- MX
- Mexico
- Prior art keywords
- metabolite
- tumour cells
- bound
- radiopharmaceutical
- radionuclide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
Abstract
Esta invención se refiere a nuevos conjugados radiofarmacéuticos para el uso en métodos mejorados de diagnóstico y tratamiento de cáncer. El conjugado radiofarmacéutico comprende, en secuencia: un metabolito que se dirige a células tumorales, ligado a un agente quelante capaz de contener un radionúclido, ligado a un conector capaz de la unión con un agente EPR in vitro o in vivo; o un agente quelante capaz de contener un radionúclido, ligado a un metabolito que se dirige a células tumorales, ligado a un conector capaz de la unión con un agente EPR in vitro o in vivo. Los conjugados radiofarmacéuticos de la presente invención proporcionan sistemas de suministro de radionúclidos dirigidos activos y pasivos que pueden ayudar a mejorar la biodistribución y la toxicidad farmacológica de los radiofarmacéuticos usados para el diagnóstico y la terapia de cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1417067.4A GB201417067D0 (en) | 2014-09-26 | 2014-09-26 | Radiopharmaceutical conjugate |
PCT/IB2015/057378 WO2016046793A2 (en) | 2014-09-26 | 2015-09-25 | Radiopharmaceutical conjugate |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017003886A true MX2017003886A (es) | 2018-01-12 |
Family
ID=51901213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003886A MX2017003886A (es) | 2014-09-26 | 2015-09-25 | Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales. |
Country Status (14)
Country | Link |
---|---|
US (1) | US10874753B2 (es) |
EP (1) | EP3197504A2 (es) |
JP (1) | JP6821558B2 (es) |
KR (1) | KR102276804B1 (es) |
CN (1) | CN107106709B (es) |
AR (1) | AR102105A1 (es) |
AU (1) | AU2015323328B2 (es) |
BR (1) | BR112017005985A2 (es) |
CA (1) | CA2962525C (es) |
GB (1) | GB201417067D0 (es) |
MX (1) | MX2017003886A (es) |
RU (1) | RU2017114360A (es) |
WO (1) | WO2016046793A2 (es) |
ZA (1) | ZA201702638B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105999308B (zh) * | 2016-06-29 | 2020-08-07 | 华中科技大学同济医学院附属协和医院 | 一种肿瘤靶向性mri造影剂及其制备方法 |
CN106377527B (zh) * | 2016-09-05 | 2019-02-26 | 郑州大学 | 开链吡啶羧酸衍生物H2dedpa在抗菌领域的应用 |
US11357873B2 (en) | 2016-09-19 | 2022-06-14 | The Hong Kong Polytechnic University | Chiral cyclen compounds and their uses |
PT3568205T (pt) * | 2017-01-12 | 2023-10-26 | Radiomedix Inc | Tratamento de células de cancro que sobrexpressam recetores de somatostatina com a utilização de derivados de ocreótido quelado a radioisótopos |
KR20200004861A (ko) | 2017-05-05 | 2020-01-14 | 퓨전 파마슈티칼즈 인크. | Igf-1r 모노클로날 항체 및 그의 용도 |
US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
EA201992595A1 (ru) | 2017-05-05 | 2020-04-21 | Фьюжн Фармасьютикалс Инк. | Усиление фармакокинетики бифункциональных хелатов и их применения |
EA202090116A1 (ru) * | 2017-07-18 | 2020-05-14 | ВИРИФАРМ ЭНТЕРПРАЙЗЕС, ЭлЭлСи | Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения |
AU2018388467A1 (en) * | 2017-12-18 | 2020-06-11 | Janssen Biotech, Inc. | Radiolabeling of polypeptides |
MX2018003175A (es) * | 2018-03-14 | 2019-09-16 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. |
WO2019211843A1 (en) * | 2018-04-30 | 2019-11-07 | Bar-Ilan University | Polymeric core-shell particles |
US20220040338A1 (en) * | 2018-10-16 | 2022-02-10 | Nant Holdings Ip, Llc | Alpha Emitter Compositions And Methods |
KR20220139883A (ko) * | 2020-01-10 | 2022-10-17 | 퓨전 파마슈티칼즈 인크. | 마크로시클릭 킬레이트 및 그의 용도 |
US20240050600A1 (en) * | 2020-08-14 | 2024-02-15 | Clarity Pharmaceuticals Ltd | Radiopharmaceuticals, uses thereof, and methods for the production thereof |
CN114949267A (zh) * | 2021-03-18 | 2022-08-30 | 米度(南京)生物技术有限公司 | 药物缀合物及其应用 |
US11554184B2 (en) | 2021-03-26 | 2023-01-17 | Vyripharm Enterprises, Inc. | Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases |
WO2022251516A2 (en) * | 2021-05-26 | 2022-12-01 | Cornell University | Complexes with acyclic chelators and their use in targeted radiotherapy of cancer |
WO2023219582A1 (en) * | 2022-05-13 | 2023-11-16 | Eczacibaşi Monrol Nükleer Ürünler Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Radiopharmaceuticals with high stability and radiolabeling efficiency and theranostic kit comprising said radiopharmaceuticals |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4824659A (en) * | 1985-06-07 | 1989-04-25 | Immunomedics, Inc. | Antibody conjugates |
DK172629B1 (da) | 1986-02-14 | 1999-03-22 | Nihon Mediphysics Co Ltd | Reaktive højmolekylære forbindelser med mindst én fri aminogruppe, højmolekylære forbindelser kombineret med et fysiologisk |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
FI923350A (fi) | 1991-07-26 | 1993-01-27 | Hoechst Ag | Foerfarande foer maerkning av substanser med teknetium eller renium |
EP0683676A4 (en) * | 1993-02-02 | 1998-09-30 | Neorx Corp | BIODISTRIBUTION DIRECTED FROM SMALL MOLECULES. |
US20040067196A1 (en) | 2000-10-11 | 2004-04-08 | Brunke Karen J. | Targeted therapeutic lipid constructs |
EP1389090A2 (en) | 2001-04-26 | 2004-02-18 | Board of Regents, The University of Texas System | Diagnostic imaging compositions, their methods of synthesis and use |
JP2005519861A (ja) * | 2001-07-27 | 2005-07-07 | ターゲサム・インコーポレーテッド | 治療剤及び撮像剤としての脂質構築物 |
ATE435035T1 (de) | 2003-01-13 | 2009-07-15 | Bracco Imaging Spa | Verbesserte linker für radiopharmazeutische verbindungen |
KR20080072686A (ko) | 2005-11-29 | 2008-08-06 | 말린크로트, 인코포레이티드 | 이관능성 금속 킬레이팅 컨쥬게이트 |
EP2007435B1 (en) | 2006-03-31 | 2019-12-18 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
WO2007121453A2 (en) | 2006-04-17 | 2007-10-25 | The Regents Of The University Of California | 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents |
KR20090014164A (ko) | 2006-04-19 | 2009-02-06 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 세포 영상화 및 치료를 위한 조성물 및 방법 |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
US20100179303A1 (en) | 2007-04-27 | 2010-07-15 | The Regents Of The University Of California | Site-specific conjugation of ligands to nanoparticles |
CN101333259A (zh) * | 2008-07-31 | 2008-12-31 | 江苏省原子医学研究所 | 肝受体显像剂99mTc-半乳糖基化人血清白蛋白融合干扰素的制备及其应用 |
WO2010062557A2 (en) * | 2008-10-27 | 2010-06-03 | University Of Virginia Patent Foundation | Multimodal imaging of atherosclerotic plaque targeted to lox-1 |
WO2010059315A1 (en) * | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
WO2010062381A1 (en) | 2008-11-28 | 2010-06-03 | Robert Shorr | Organelle-specific drug delivery |
JP2012510477A (ja) | 2008-12-02 | 2012-05-10 | ザ ユニバーシティー オブ メルボルン | 放射性医用薬剤としての窒素含有大環状結合体 |
EP2454271A4 (en) | 2009-07-15 | 2015-08-12 | Univ California | PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING |
WO2011008985A2 (en) | 2009-07-15 | 2011-01-20 | Georgia Tech Research Corporation | Methods and compositions for improved delivery of therapeutic and diagnostic agents |
GB201019118D0 (en) | 2010-11-11 | 2010-12-29 | King S College | Conjugates and their uses in molecular imaging |
WO2012153297A1 (en) * | 2011-05-11 | 2012-11-15 | Ramot At Tel-Aviv University Ltd. | Targeted polymeric conjugates and uses thereof |
PL228735B1 (pl) | 2012-02-27 | 2018-04-30 | Inst Immunologii I Terapii Doswiadczalnej Pan | Zastosowanie koniugatu składającego się z nośnika i zawiązanego z nim kowalencyjnie leku |
TW201511774A (zh) * | 2013-09-18 | 2015-04-01 | Iner Aec Executive Yuan | 放射性標誌之主動標靶性醫藥組合物及其用途 |
-
2014
- 2014-09-26 GB GBGB1417067.4A patent/GB201417067D0/en not_active Ceased
-
2015
- 2015-09-25 RU RU2017114360A patent/RU2017114360A/ru not_active Application Discontinuation
- 2015-09-25 CN CN201580059882.1A patent/CN107106709B/zh active Active
- 2015-09-25 EP EP15778046.1A patent/EP3197504A2/en active Pending
- 2015-09-25 MX MX2017003886A patent/MX2017003886A/es unknown
- 2015-09-25 BR BR112017005985A patent/BR112017005985A2/pt active Search and Examination
- 2015-09-25 KR KR1020177011386A patent/KR102276804B1/ko active IP Right Grant
- 2015-09-25 JP JP2017516683A patent/JP6821558B2/ja active Active
- 2015-09-25 CA CA2962525A patent/CA2962525C/en active Active
- 2015-09-25 WO PCT/IB2015/057378 patent/WO2016046793A2/en active Application Filing
- 2015-09-25 US US15/514,138 patent/US10874753B2/en active Active
- 2015-09-25 AU AU2015323328A patent/AU2015323328B2/en active Active
- 2015-09-28 AR ARP150103118A patent/AR102105A1/es unknown
-
2017
- 2017-04-12 ZA ZA2017/02638A patent/ZA201702638B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170095810A (ko) | 2017-08-23 |
WO2016046793A3 (en) | 2016-06-09 |
WO2016046793A2 (en) | 2016-03-31 |
CA2962525A1 (en) | 2016-03-31 |
ZA201702638B (en) | 2021-08-25 |
JP2017530131A (ja) | 2017-10-12 |
JP6821558B2 (ja) | 2021-01-27 |
RU2017114360A (ru) | 2018-10-26 |
CN107106709A (zh) | 2017-08-29 |
EP3197504A2 (en) | 2017-08-02 |
CA2962525C (en) | 2022-08-30 |
RU2017114360A3 (es) | 2019-04-04 |
CN107106709B (zh) | 2021-04-06 |
AR102105A1 (es) | 2017-02-01 |
AU2015323328A1 (en) | 2017-05-04 |
GB201417067D0 (en) | 2014-11-12 |
US10874753B2 (en) | 2020-12-29 |
BR112017005985A2 (pt) | 2017-12-19 |
US20170296684A1 (en) | 2017-10-19 |
AU2015323328B2 (en) | 2021-02-25 |
KR102276804B1 (ko) | 2021-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017003886A (es) | Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales. | |
ZA202004099B (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
AU2020201329C1 (en) | Conjugates for treating diseases caused by PSMA expressing cells | |
PH12017500023A1 (en) | Targeted conjugates and particles and formulations thereof | |
MX2021008977A (es) | Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. | |
MX343405B (es) | Complejos que emiten alfa-particulas objetivo que comprenden radionuclido de torio e hidroxipiridinona que contiene ligando. | |
PH12019502278A1 (en) | Conjugation of a cytotoxic drug with bis-linkage | |
NZ710746A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
MX2013003452A (es) | Conjugados de amatoxina con enlazantes mejorados. | |
EA032986B1 (ru) | Пирролобензодиазепины | |
NZ737471A (en) | Hydrophilic linkers for conjugation | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
NZ701573A (en) | Carriers for improved drug delivery | |
EA032867B9 (ru) | Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты | |
PH12018500701A1 (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
MX2019004963A (es) | Conjugados y particulas especificos del sstr y formulaciones de los mismos. | |
MX2018000239A (es) | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. | |
PH12017502392A1 (en) | Targeted conjugates and particles and formulations thereof | |
MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
NZ719936A (en) | Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses | |
MX2018006226A (es) | Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo. | |
WO2019147338A3 (en) | Radiopharmaceuticals and methods of use thereof | |
SG10201805160UA (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
EP4212181A3 (en) | Methylene carbamate linkers for use with targeted-drug conjugates | |
IN2013DE03280A (es) |